Free Trial

Kiora Pharmaceuticals (KPRX) Competitors

Kiora Pharmaceuticals logo
$3.52
-0.15 (-4.09%)
(As of 11/5/2024 ET)

KPRX vs. TTPH, SRZN, VTVT, ACHL, CLNN, RLYB, DRRX, CARM, PRPH, and OKYO

Should you be buying Kiora Pharmaceuticals stock or one of its competitors? The main competitors of Kiora Pharmaceuticals include Tetraphase Pharmaceuticals (TTPH), Surrozen (SRZN), vTv Therapeutics (VTVT), Achilles Therapeutics (ACHL), Clene (CLNN), Rallybio (RLYB), DURECT (DRRX), Carisma Therapeutics (CARM), ProPhase Labs (PRPH), and OKYO Pharma (OKYO). These companies are all part of the "medical" sector.

Kiora Pharmaceuticals vs.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

Kiora Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 172.11%. Given Kiora Pharmaceuticals' higher possible upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Tetraphase Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tetraphase Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Kiora Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.50

Kiora Pharmaceuticals has a net margin of 0.00% compared to Tetraphase Pharmaceuticals' net margin of -798.18%. Kiora Pharmaceuticals' return on equity of 15.57% beat Tetraphase Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Tetraphase Pharmaceuticals-798.18% -210.86% -121.73%
Kiora Pharmaceuticals N/A 15.57%11.34%

Tetraphase Pharmaceuticals has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.29, meaning that its stock price is 129% less volatile than the S&P 500.

Tetraphase Pharmaceuticals received 368 more outperform votes than Kiora Pharmaceuticals when rated by MarketBeat users. However, 72.73% of users gave Kiora Pharmaceuticals an outperform vote while only 67.13% of users gave Tetraphase Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Tetraphase PharmaceuticalsOutperform Votes
384
67.13%
Underperform Votes
188
32.87%
Kiora PharmaceuticalsOutperform Votes
16
72.73%
Underperform Votes
6
27.27%

42.3% of Tetraphase Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 5.7% of Tetraphase Pharmaceuticals shares are owned by company insiders. Comparatively, 1.5% of Kiora Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kiora Pharmaceuticals has lower revenue, but higher earnings than Tetraphase Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tetraphase Pharmaceuticals$7.38M2.17-$70.08M-$22.85-0.10
Kiora PharmaceuticalsN/AN/A-$12.51MN/AN/A

In the previous week, Kiora Pharmaceuticals had 2 more articles in the media than Tetraphase Pharmaceuticals. MarketBeat recorded 2 mentions for Kiora Pharmaceuticals and 0 mentions for Tetraphase Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 0.45 beat Tetraphase Pharmaceuticals' score of 0.00 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Tetraphase Pharmaceuticals Neutral
Kiora Pharmaceuticals Neutral

Summary

Kiora Pharmaceuticals beats Tetraphase Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KPRX vs. The Competition

MetricKiora PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$10.69M$7.03B$5.24B$8.52B
Dividend YieldN/A7.95%5.06%4.17%
P/E RatioN/A5.5388.1712.58
Price / SalesN/A398.681,681.6994.04
Price / CashN/A22.2833.8731.42
Price / Book0.515.694.754.58
Net Income-$12.51M$152.35M$116.51M$224.55M
7 Day Performance-4.55%-1.75%-0.83%-0.83%
1 Month Performance6.37%14.51%5.48%2.97%
1 Year Performance-34.15%37.44%33.91%25.23%

Kiora Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KPRX
Kiora Pharmaceuticals
3.781 of 5 stars
$3.52
-4.1%
$10.00
+184.1%
-34.2%$10.45MN/A0.0010Gap Down
TTPH
Tetraphase Pharmaceuticals
N/A$2.20
flat
N/A+0.0%$15.98M$7.38M-0.12119
SRZN
Surrozen
2.018 of 5 stars
$11.88
-10.2%
N/A+84.6%$42.41M$12.50M0.0042News Coverage
Gap Down
VTVT
vTv Therapeutics
N/A$14.00
-0.2%
N/A-10.3%$42.23M$2.02M-2.049Gap Down
ACHL
Achilles Therapeutics
1.9588 of 5 stars
$1.03
flat
$4.00
+290.2%
+18.7%$42.12MN/A-0.64250Upcoming Earnings
CLNN
Clene
3.3952 of 5 stars
$5.67
-7.2%
$72.33
+1,175.7%
-29.8%$41.90M$650,000.00-1.27100
RLYB
Rallybio
3.1176 of 5 stars
$1.02
+1.0%
$10.00
+880.4%
-75.4%$41.90MN/A-0.5740
DRRX
DURECT
2.738 of 5 stars
$1.35
+0.7%
$21.00
+1,455.6%
-50.5%$41.59M$8.55M-2.2180Upcoming Earnings
Analyst Forecast
CARM
Carisma Therapeutics
2.587 of 5 stars
$1.05
+5.0%
$7.00
+566.7%
-67.6%$41.54M$14.92M-0.5920News Coverage
Gap Up
PRPH
ProPhase Labs
3.0594 of 5 stars
$2.19
+2.3%
$11.00
+402.3%
-51.8%$40.83M$44.38M-1.81130Positive News
OKYO
OKYO Pharma
3.3516 of 5 stars
$1.16
-3.3%
$7.00
+503.4%
-35.6%$40.60MN/A0.007

Related Companies and Tools


This page (NASDAQ:KPRX) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners